Patents by Inventor Mario Filion
Mario Filion has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8580257Abstract: Novel monoclonal antibodies that specifically bind to KAAG1 are described. In some embodiments, the antibodies block the biological activity of KAAG1 and are useful in composition in certain cancers, more particularly in cancers that have increased cell surface expression of KAAG1, such as ovarian, renal, lung, colorectal, breast, brain, and prostate cancer, as well as melanoma. The invention also relates to cells expressing the monoclonal antibodies and antigen binding fragments such as humanized and chimeric antibodies. Additionally, method of detecting and treating cancer using the antibodies and fragments are also disclosed.Type: GrantFiled: July 20, 2011Date of Patent: November 12, 2013Assignee: Alethia Biotherapeutics Inc.Inventors: Gilles Bernard Tremblay, Mario Filion
-
Patent number: 8540988Abstract: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling, variants and derivatives of the polynucleotides and corresponding polypeptides, uses of the polynucleotides, polypeptides, variants and derivatives, and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are the isolation and identification of polynucleotides, polypeptides variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.Type: GrantFiled: June 2, 2011Date of Patent: September 24, 2013Assignee: Alethia Biotherapeutics Inc.Inventors: Roy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion
-
Patent number: 8444975Abstract: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding polypeptides; uses of the polynucleotides, polypeptides, variants and derivatives; and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are, the isolation and identification of polynucleotides, polypeptides, variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.Type: GrantFiled: May 23, 2012Date of Patent: May 21, 2013Assignee: Alethia Biotherapeutics Inc.Inventors: Roy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion
-
Patent number: 8431126Abstract: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding polypeptides; uses of the polynucleotides, polypeptides, variants and derivatives; and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are, the isolation and identification of polynucleotides, polypeptides, variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.Type: GrantFiled: July 25, 2012Date of Patent: April 30, 2013Assignee: Alethia Biotherapeutics Inc.Inventors: Roy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion
-
Publication number: 20130039915Abstract: Novel antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein In some embodiments, the antibodies or antigen binding fragments may block the biological activity of Siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of Siglec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts. The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.Type: ApplicationFiled: October 6, 2010Publication date: February 14, 2013Applicant: ALETHIA BIOTHERAPEUTICS INCInventors: Gilles Bernard Tremblay, Mario Filion, Matthew Stuible
-
Publication number: 20120308561Abstract: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding polypeptides; uses of the polynucleotides, polypeptides, variants and derivatives; and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are, the isolation and identification of polynucleotides, polypeptides, variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.Type: ApplicationFiled: May 23, 2012Publication date: December 6, 2012Applicant: ALETHIA BIOTHERAPEUTICS INC.Inventors: Roy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion
-
Publication number: 20120288498Abstract: The present invention relates to polynucleotide and polypeptide sequences which are differentially expressed in cancer cells compared to normal cells. The present invention more particularly relates to the use of these sequences in the diagnosis, prognosis or treatment of cancer and in the detection of cancer cells.Type: ApplicationFiled: June 7, 2012Publication date: November 15, 2012Applicant: ALETHIA BIOTHERAPEUTICS INC.Inventors: Roy Rabindranauth SOOKNANAN, Gilles Bernard TREMBLAY, Mario FILION
-
Publication number: 20120288503Abstract: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding polypeptides; uses of the polynucleotides, polypeptides, variants and derivatives; and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are, the isolation and identification of polynucleotides, polypeptides, variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.Type: ApplicationFiled: July 25, 2012Publication date: November 15, 2012Applicant: ALETHIA BIOTHERAPEUTICS, INC.Inventors: Roy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion
-
Publication number: 20120282251Abstract: Novel antibodies and antigen binding fragments that specifically bind to clusterin are described. In some embodiments, the antibodies block the biological activity of clusterin and are useful in composition in certain cancers, more particularly in cancers, such as endometrial carcinoma, breast carcinoma, hepatocellular carcinoma, prostate carcinoma, a renal cell carcinoma, ovarian carcinoma, pancreatic carcinoma, and colorectal carcinoma. The invention also relates to cells expressing the humanized or hybrid antibodies. Additionally, methods of detecting and treating cancer using the antibodies and fragments are also disclosed.Type: ApplicationFiled: November 24, 2010Publication date: November 8, 2012Inventors: Gilles Bernard Tremblay, Mario Filion, Traian Sulea
-
Patent number: 8216582Abstract: The present invention relates to polynucleotide and polypeptide sequences which are differentially expressed in cancer cells compared to normal cells. The present invention more particularly relates to the use of these sequences in the diagnosis, prognosis or treatment of cancer and in the detection of cancer cells.Type: GrantFiled: June 22, 2007Date of Patent: July 10, 2012Assignee: Alethia Biotherapeutics Inc.Inventors: Roy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion
-
Publication number: 20120128661Abstract: The present invention relates to polynucleotide and polypeptide sequences which are differentially expressed in cancer cells compared to normal cells. The present invention more particularly relates to the use of these sequences in the diagnosis, prognosis or treatment of cancer and in the detection of cancer cells.Type: ApplicationFiled: June 2, 2011Publication date: May 24, 2012Applicant: ALETHIA BIOTHERAPEUTICS INC.Inventors: Roy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion
-
Patent number: 8168181Abstract: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding polypeptides; uses of the polynucleotides, polypeptides, variants and derivatives; and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are, the isolation and identification of polynucleotides, polypeptides, variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.Type: GrantFiled: October 16, 2009Date of Patent: May 1, 2012Assignee: Alethia Biotherapeutics, Inc.Inventors: Roy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion
-
Publication number: 20120093819Abstract: Novel monoclonal antibodies that specifically bind to KAAG1 are described. In some embodiments, the antibodies block the biological activity of KAAG1 and are useful in composition in certain cancers, more particularly in cancers that have increased cell surface expression of KAAG1, such as ovarian, renal, lung, colorectal, breast, brain, and prostate cancer, as well as melanoma. The invention also relates to cells expressing the monoclonal antibodies and antigen binding fragments such as humanized and chimeric antibodies. Additionally, method of detecting and treating cancer using the antibodies and fragments are also disclosed.Type: ApplicationFiled: July 20, 2011Publication date: April 19, 2012Applicants: NATIONAL RESEARCH COUNCIL OF CANADA, ALETHIA BIOTHERAPEUTICS INC.Inventors: Gilles Bernard Tremblay, Mario Filion
-
Publication number: 20110311526Abstract: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling, variants and derivatives of the polynucleotides and corresponding polypeptides, uses of the polynucleotides, polypeptides, variants and derivatives, and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are the isolation and identification of polynucleotides, polypeptides variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.Type: ApplicationFiled: June 2, 2011Publication date: December 22, 2011Applicant: ALETHIA BIOTHERAPEUTICS INC.Inventors: Roy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion
-
Publication number: 20110293604Abstract: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding polypeptides; uses of the polynucleotides, polypeptides, variants and derivatives; and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are, the isolation and identification of polynucleotides, polypeptides, variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.Type: ApplicationFiled: April 7, 2011Publication date: December 1, 2011Applicant: ALETHIA BIOTHERAPEUTICS INC.Inventors: Roy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion
-
Publication number: 20110286924Abstract: The present invention relates to polynucleotide and polypeptide sequences of a novel human endogenous retroviral ERV3 variant which is differentially expressed in ovarian cancer cells when compared to normal cells. The present invention more particularly relates to the use of these polynucleotide and polypeptide in the diagnosis, prognosis or treatment of cancer and in the detection of cancer cells.Type: ApplicationFiled: December 23, 2008Publication date: November 24, 2011Applicant: ALETHIA BIOTHERAPEUTICS INCInventors: Gilles Bernard Tremblay, Mario Filion, Anna Moraitis
-
Publication number: 20110223107Abstract: Novel monoclonal antibodies that specifically bind to KAAG1 are described. In some embodiments, the antibodies block the biological activity of KAAG1 and are useful in composition in certain cancers, more particularly in cancers that have increased cell surface expression of KAAG1, such as ovarian, renal, lung, colorectal, breast, brain, and prostate cancer, as well as melanoma. The invention also relates to cells expressing the monoclonal antibodies and antigen binding fragments such as humanized and chimeric antibodies. Additionally, methods of detecting and treating cancer using the antibodies and fragments are also disclosed.Type: ApplicationFiled: November 3, 2009Publication date: September 15, 2011Applicants: ALETHIA BIOTHERAPEUTICS INC., NATIONAL RESEARCH COUNCIL OF CANADAInventors: Gilles Bernard Tremblay, Mario Filion, Traian Sulea
-
Patent number: 7989160Abstract: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling, variants and derivatives of the polynucleotides and corresponding polypeptides, uses of the polynucleotides, polypeptides, variants and derivatives, and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are the isolation and identification of polynucleotides polypeptides variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.Type: GrantFiled: February 13, 2007Date of Patent: August 2, 2011Assignee: Alethia Biotherapeutics Inc.Inventors: Roy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion
-
Patent number: 7947436Abstract: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding polypeptides; uses of polynucleotides, polypeptides, variants and derivatives; and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are, the isolation and identification of polynucleotides, polypeptides, variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.Type: GrantFiled: December 13, 2005Date of Patent: May 24, 2011Assignee: Alethia Biotherapeutics Inc.Inventors: Roy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion
-
Publication number: 20100104575Abstract: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding polypeptides; uses of the polynucleotides, polypeptides, variants and derivatives; and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are, the isolation and identification of polynucleotides, polypeptides, variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.Type: ApplicationFiled: October 16, 2009Publication date: April 29, 2010Applicant: ALETHIA BIOTHERAPEUTICS INC.Inventors: Roy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion